ANRO

— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies — — Trial design and MADRS primary endpoint aligned with FDA standards in depression, potentially supporting a single Phase 3 registrational pathway — — Prior Phase 2a demonstrated robust antidepressant effects of ALTO-207 and favorable tolerability — — Topline data expected in 2H 2027 — Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatmen

EFFECT - Alto Neuroscience, Inc. (0001999480) (Filer)

S-3 - Alto Neuroscience, Inc. (0001999480) (Filer)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC (p=0.052) — — Alto has developed a modified-release, once-daily oral formulation of ALTO-101; the Company plans to explore partnering opportunities for this formulation — — Development of ALTO-207 remains the top priority for the Company; Phase 2b on track to initiate in 1H 2026 — Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 proof-of-concept (POC) clinic

DEFA14A - Alto Neuroscience, Inc. (0001999480) (Filer)

DEF 14A - Alto Neuroscience, Inc. (0001999480) (Filer)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

– Financing led by Commodore Capital with participation from new and existing biotech focused investors – –  Alto expects to use the proceeds of the financing to support the development of ALTO-207 in Treatment Resistant Depression through a planned Phase 3 study and to a potential NDA submission – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the "PIPE") for gross proceeds of approximately

S-8 - Alto Neuroscience, Inc. (0001999480) (Filer)

10-K - Alto Neuroscience, Inc. (0001999480) (Filer)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

– Acquisition of ALTO-207 targets Treatment-Resistant Depression (TRD) with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 – – External PAX-D study published in The Lancet Psychiatry demonstrated a 0.87 effect size for the core mechanism of ALTO-207; this effect represents a significantly larger effect size than current standard-of-care treatments – – ALTO-101 granted FDA Fast Track Designation for CIAS; Topline Phase 2 Proof-of Concept data expected around the end of 1Q 2026 – – Year-end cash balance of $177 million expected to fund planned operations into 2028, covering four key data readouts across Alto's precision psychiatry pip

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET. The presentation will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto's website and a replay will be available following the presentation. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobi

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 26, 2026 /CNW/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that milestone this week, signaling a potential shift in how regulators and investors view psychedelic-based psychiatry[1]. The pathway is widening at the federal level, where the Drug Enforcement Administration raised its 2026 psilocybin production quota by 67%[2]. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), Relmada Therapeutics (NASDAQ:RLMD), Alto Neuroscience (NYSE:ANRO), and Axsome

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference, March 2-5, 2026 Format: Fireside chat and one-on-one meetings Presentation Date & Time: March 3, 2026, 1:50 pm EST Location: Boston, MA Jefferies 2026 Biotech on the Beach Summit, March 10-11, 2026 Format: One-on-one investor meetings Location: Miami, FL Available presentations will be accessible via a live webcast on the

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)